- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Interventions
- becatecarin
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma
- Interventions
- Zimberelimab, Domvanalimab
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Rectal Cancer, Hepatobiliary Cancer, Colon Cancer
- Interventions
- Usual Care, Perioperative Geriatrics Intervention
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors
- Interventions
- STM 434, Liposomal doxorubicin
- Drug
- Lead sponsor
- Santa Maria Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Cancer
- Interventions
- Minimally invasive hemodynamic monitoring
- Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Interventions
- filgrastim, pegylated liposomal doxorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Providence, Rhode Island
- Conditions
- Hepatobiliary Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Ampullary Cancer, Pancreatic Carcinoma
- Interventions
- ctDNA Blood Collection
- Diagnostic Test
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Pancreatic Cancer
- Interventions
- Computed Tomography (CT), Questionnaire
- Procedure · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinomas, Amyloidosis, Anal Cancer, Anemia, Cholangiocarcinoma of the Extrahepatic Bile Duct, Transitional Cell Carcinoma of Bladder, Bone Marrow Transplant Failure, Bone Cancer, Cancer of Brain and Nervous System, Breast Cancer, Carcinoma of the Large Intestine, Endocrine Cancer, Esophageal Cancer, Eye Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Gynecologic Cancers, Head and Neck Cancers, Hepatobiliary Neoplasm, Kidney (Renal Cell) Cancer, Leukemia, Lung Cancer, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mesothelioma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Neuroendocrine Tumors, Myeloproliferative Disorders, Pancreatic Cancer, Prostate Cancer, Skin Cancer, Soft Tissue Sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer
- Interventions
- Not listed
- Lead sponsor
- Daniel Bernstein
- Other
- Eligibility
- Up to 40 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Carcinoma, Hepatocellular, Hepatobiliary Neoplasm, Liver Carcinoma
- Interventions
- TACE, SBRT
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
- Interventions
- FT-2102, Azacitidine, Nivolumab, Gemcitabine and Cisplatin
- Drug · Biological
- Lead sponsor
- Forma Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 14
- States / cities
- Gilbert, Arizona • Aurora, Colorado • Miami, Florida + 10 more
- Conditions
- Biliary Tract Cancer
- Interventions
- NUC-1031, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- NuCana plc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 773 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Whittier, California • Aurora, Colorado + 23 more
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatobiliary Cancer
- Interventions
- Target Navigation Pilot Program
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hepatocellular Carcinoma, Biliary Tract Cancer, Cirrhosis, Liver Diseases
- Interventions
- Blood samples
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,865 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2024
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Chicago, Illinois • Rochester, Minnesota + 1 more
- Conditions
- Gastrointestinal Neoplasms, Gynecologic Cancers, Gynecologic Cancers Cervical Cancer, Gastric (Stomach) Cancer, Gastro-Esophageal(GE) Junction Cancer, Gastrointenstinal Stromal Tumor (GIST), Colon/Rectal Cancer, Colon/Rectal Cancer Colon Cancer, Colon/Rectal Cancer Rectal Cancer, Colon/Rectal Cancer Anal Cancer, Anal Cancer, Hepatobiliary Cancers, Hepatobiliary Cancers Liver, Pancreatic Cancer
- Interventions
- Blood Draw, Frozen Tumor Specimens
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2099
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Esophageal Carcinoma, Gastric Cancer (Diagnosis), Colorectal Adenocarcinoma, Appendiceal Adenocarcinoma, Small Bowel Adenocarcinoma, Hepatobiliary Carcinoma in Situ
- Interventions
- Paclitaxel Q2W, Paclitaxcel Q3W
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Hepatobiliary Cancer, Cholangiocarcinoma, Liver Metastases
- Interventions
- Resistance Training, Aerobic Training
- Behavioral
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Hepatocellular Carcinoma, Primary Liver Cancer, Bile Duct Cancer, Pancreatic Cancer, Gallbladder Cancer, Colorectal Carcinoma, Liver Metastases
- Interventions
- Collaborative Care, Enhanced usual Care
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hepatobiliary Cancers
- Interventions
- Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Interventions
- dolastatin 10
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 11
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more
- Conditions
- Pancreas Cancer, Hepatobiliary Cancer, Patient Engagement
- Interventions
- Not listed
- Lead sponsor
- GMG Arcdata LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Colorectal Cancer, Hepatobiliary Cancer, Gynecologic Cancer
- Interventions
- Moderate continuous exercise, High intensity interval exercise
- Behavioral
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Liver Irradiation
- Radiation
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Solid Tumor
- Interventions
- Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D)
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more